NOTCH1 and small cell lung carcinoma: Similarly, among SCLC-A and SCLC-N tumors, high NOTCH1 expression was significantly associated with longer OS with atezolizumab compared with placebo (HR 0.52; 95% CI, 0.33–0.83; unadjusted P = 0.005), whereas low NOTCH1 expression was not (HR 1.12; 95% CI, 0.72–1.74; unadjusted P = 0.62) (Supplemental Figure 3B).